Wedbush Lowers Earnings Estimates for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Wedbush reduced their Q4 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a note issued to investors on Monday, February 24th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $0.12 per share for the quarter, down from their previous forecast of $0.15. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2026 earnings at $1.35 EPS, FY2027 earnings at $3.23 EPS and FY2028 earnings at $3.75 EPS.

A number of other equities analysts also recently weighed in on TVTX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research note on Friday, February 21st. Barclays boosted their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Citigroup increased their price objective on Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. Canaccord Genuity Group boosted their target price on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Finally, Scotiabank raised their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Stock Up 1.8 %

Shares of NASDAQ TVTX opened at $21.03 on Wednesday. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $25.29. The firm’s 50-day simple moving average is $19.90 and its 200 day simple moving average is $16.89. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -5.13 and a beta of 0.72.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The business had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%.

Institutional Trading of Travere Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Rock Springs Capital Management LP increased its position in shares of Travere Therapeutics by 6.2% during the fourth quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company’s stock worth $86,641,000 after acquiring an additional 289,173 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Travere Therapeutics by 28.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company’s stock worth $41,974,000 after purchasing an additional 534,500 shares during the period. Driehaus Capital Management LLC increased its holdings in Travere Therapeutics by 608.1% during the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company’s stock worth $38,637,000 after purchasing an additional 1,904,733 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Travere Therapeutics by 36.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company’s stock valued at $37,875,000 after purchasing an additional 583,836 shares during the period. Finally, Emerald Advisers LLC lifted its holdings in shares of Travere Therapeutics by 8.4% in the fourth quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company’s stock valued at $37,030,000 after purchasing an additional 165,085 shares in the last quarter.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, CFO Christopher R. Cline sold 5,192 shares of Travere Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $104,463.04. Following the transaction, the chief financial officer now directly owns 90,038 shares in the company, valued at approximately $1,811,564.56. The trade was a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Sandra Calvin sold 54,244 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at approximately $1,360,250. The trade was a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 206,335 shares of company stock worth $4,453,012 in the last ninety days. Company insiders own 4.06% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.